Clinically Bharat

We Can Cover You

Healthcare

Novo Nordisk’s Ozempic shortage expected to continue into Q4, Health News, ET HealthWorld

Email :74

Bengaluru: Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased demand and along with capacity constraints at some of its manufacturing sites.

In a note published by the European Medicines Agency (EMA) on Monday, the obesity drug maker recommended healthcare workers continue limiting treatment initiation of new patients on Ozempic and its other diabetic drug, Victoza, until the supply situation improves.

(Reporting by Shanima A in Bengaluru; Editing by Alex Richardson)

  • Published On Sep 3, 2024 at 02:35 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post